The U.S. Centers for Disease Control and Prevention (CDC) currently recommends that adolescents receive one dose of meningococcal conjugate vaccine at age 11 or 12, followed by a booster vaccination at age 16. And as of this week, with an FDA approval for booster immunization, Sanofi's ($SNY) Menactra can now fulfill both of those guidelines. The new nod could boost sales of the French drugmaker's vaccine, a lift it could use after Menactra's top-line haul in 2013 sank to €424 million in a 21.5% slide. Release | More